MCID: SXD002
MIFTS: 49

Sex Development Disorder

Categories: Endocrine diseases

Aliases & Classifications for Sex Development Disorder

MalaCards integrated aliases for Sex Development Disorder:

Name: Sex Development Disorder 12 15
Disorders of Sex Development 45
Sex Differentiation Disease 12
Disorder of Sex Development 41

Classifications:



External Ids:

Disease Ontology 12 DOID:1923
MeSH 45 D012734
UMLS 74 C0036875

Summaries for Sex Development Disorder

MalaCards based summary : Sex Development Disorder, also known as disorders of sex development, is related to aromatase deficiency and mixed gonadal dysgenesis. An important gene associated with Sex Development Disorder is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Corticotropin-releasing hormone signaling pathway. The drugs Menotropins and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and bone, and related phenotypes are endocrine/exocrine gland and integument

Wikipedia : 77 Disorders of sex development (DSD) are medical conditions involving the reproductive system. More... more...

Related Diseases for Sex Development Disorder

Diseases related to Sex Development Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 186, show less)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 32.8 CYP19A1 GNRH1 INS
2 mixed gonadal dysgenesis 32.2 AMH AMHR2
3 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 32.1 CYP17A1 CYP21A2 POMC
4 androgen insensitivity, partial 32.1 AR CYP19A1 SHBG
5 androgen insensitivity syndrome 32.0 AR SHBG SRD5A2
6 pseudovaginal perineoscrotal hypospadias 31.9 AR CYP17A1 GNRH1 SRD5A2
7 gynecomastia 30.0 AR CYP19A1 HSD17B3 POMC PRL SHBG
8 complete androgen insensitivity syndrome 30.0 AR CYP19A1 SHBG
9 hypospadias 30.0 AR CYP17A1 HSD17B3 SRD5A2
10 lipoid congenital adrenal hyperplasia 29.9 CYP17A1 CYP19A1 CYP21A2 POMC
11 luteoma 29.8 CYP19A1 CYP21A2
12 hypogonadotropism 29.5 GNRH1 PRL
13 amenorrhea 29.3 GNRH1 POMC PRL SHBG
14 infertility 29.3 CYP19A1 GNRH1 PRL
15 cryptorchidism, unilateral or bilateral 29.3 AMH AMHR2 AR CYP19A1 GNRH1 SHBG
16 premature ovarian failure 1 28.7 AMH CYP19A1 GNRH1 PRL SHBG
17 gonadal disease 27.8 AMH AR CYP19A1 GNRH1 INS POMC
18 46,xx sex reversal 1 12.4
19 nonsyndromic 46,xx testicular disorders of sex development 12.4
20 dysmorphism-short stature-deafness-disorder of sex development syndrome 12.4
21 46,xx disorder of sex development-anorectal anomalies syndrome 12.4
22 46,xy ovotesticular disorder of sex development 12.4
23 46,xy sex reversal 3 11.9
24 46,xy sex reversal 5 11.9
25 leydig cell hypoplasia, type i 11.8
26 46,xy sex reversal 8 11.8
27 46,xx sex reversal 2 11.6
28 hypogonadotropic hypogonadism 23 without anosmia 11.6
29 leydig cell hypoplasia 11.6
30 chondrodysplasia-pseudohermaphroditism syndrome 11.5
31 denys-drash syndrome 11.3
32 adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiency 11.3
33 pseudohermaphroditism, female, with skeletal anomalies 11.3
34 17-beta hydroxysteroid dehydrogenase iii deficiency 11.3
35 46,xy sex reversal 2 11.3
36 male pseudohermaphroditism/mental retardation syndrome, verloes type 11.3
37 pontocerebellar hypoplasia, type 7 11.3
38 male pseudohermaphroditism intellectual disability syndrome, verloes type 11.3
39 46,xy sex reversal 10 11.2
40 46,xy sex reversal 6 11.2
41 mullerian aplasia and hyperandrogenism 10.9
42 46,xy sex reversal 7 10.9
43 testicular anomalies with or without congenital heart disease 10.9
44 46,xy sex reversal 9 10.9
45 46, xy disorders of sexual development 10.9
46 anorchia 10.9
47 hermaphroditism 10.4 AR SRD5A2
48 47, xxy 10.4 AR SHBG
49 noma 10.4 INS POMC
50 scleredema adultorum 10.3 INS POMC
51 persistent mullerian duct syndrome, types i and ii 10.3 AMH AMHR2
52 hyperproinsulinemia 10.3 INS SHBG
53 hypoadrenalism 10.3 POMC SHBG
54 pancreatic endocrine carcinoma 10.3 INS POMC
55 mucinoses 10.3 INS POMC
56 postmenopausal atrophic vaginitis 10.3 AR POMC SHBG
57 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.3 CYP21A2 POMC
58 acute adrenal insufficiency 10.3 CYP21A2 POMC
59 freemartinism 10.3 AMH GNRH1
60 nodular prostate 10.3 AR GNRH1
61 hypoactive sexual desire disorder 10.2 CYP19A1 SHBG
62 fetal erythroblastosis 10.2 INS POMC SHBG
63 gender identity disorder 10.2 AR CYP19A1
64 overnutrition 10.2 INS POMC SHBG
65 pigmentation disease 10.2 INS SHBG
66 sebaceous gland disease 10.2 AR SHBG
67 premature menopause 10.2 AMH GNRH1
68 adrenal cortical hypofunction 10.2 CYP21A2 POMC
69 gonadal dysgenesis 10.2
70 male reproductive organ benign neoplasm 10.2 CYP19A1 POMC
71 aromatase excess syndrome 10.1 CYP19A1 POMC
72 endometriosis of ovary 10.1 AMH CYP19A1
73 cytochrome p450 oxidoreductase deficiency 10.1 CYP17A1 CYP21A2 POMC
74 testicular leydig cell tumor 10.1 CYP17A1 CYP21A2 POMC
75 steroid inherited metabolic disorder 10.1 CYP17A1 CYP21A2 POMC
76 prostatic hyperplasia, benign 10.1 AR CYP17A1 SHBG SRD5A2
77 adrenal adenoma 10.1 CYP17A1 CYP21A2 POMC
78 adrenal carcinoma 10.1 CYP17A1 CYP21A2 POMC
79 withdrawal disorder 10.1 AR POMC
80 prostate disease 10.0 AR CYP17A1 CYP19A1
81 adenohypophysitis 10.0 POMC PRL
82 male reproductive system disease 10.0 AR CYP17A1 GNRH1 SHBG
83 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 10.0 CYP17A1 CYP21A2
84 pituitary carcinoma 10.0 POMC PRL
85 male reproductive organ cancer 10.0 AR CYP17A1 GNRH1 SHBG
86 ovarian hyperstimulation syndrome 10.0 AMH CYP19A1 GNRH1
87 sella turcica neoplasm 10.0 POMC PRL
88 leydig cell tumor 10.0 CYP17A1 CYP19A1 CYP21A2
89 tuberculum sellae meningioma 10.0 POMC PRL
90 antley-bixler syndrome 10.0 CYP17A1 CYP19A1 CYP21A2
91 nelson syndrome 10.0 POMC PRL
92 adrenal cortical adenoma 10.0 CYP17A1 CYP21A2 POMC SULT2A1
93 cortisone reductase deficiency 10.0 CYP17A1 CYP21A2 POMC SULT2A1
94 gonadoblastoma 10.0
95 disease of mental health 10.0
96 acth-secreting pituitary adenoma 9.9 POMC PRL
97 acanthosis nigricans 9.9 INS PRL SHBG
98 hyperthyroidism 9.9 INS PRL SHBG
99 precocious puberty 9.9 CYP19A1 CYP21A2 GNRH1
100 insulin-like growth factor i 9.9 INS PRL SHBG
101 sheehan syndrome 9.9 INS POMC PRL
102 abducens nerve disease 9.9 POMC PRL
103 hyperpituitarism 9.9 INS POMC PRL
104 diabetes insipidus 9.9 INS POMC PRL
105 functioning pituitary adenoma 9.9 POMC PRL
106 endocrine organ benign neoplasm 9.9 INS POMC PRL
107 thyroid gland disease 9.9 INS POMC PRL
108 cell type benign neoplasm 9.9 INS POMC PRL
109 transsexualism 9.9 AR CYP17A1 CYP19A1 CYP21A2
110 acromegaly 9.9 INS POMC PRL
111 anxiety 9.9
112 46,xx sex reversal 4 9.9
113 chromosomal triplication 9.9
114 simpson-golabi-behmel syndrome 9.9
115 pelvic varices 9.9 GNRH1 PRL SHBG
116 adenoma 9.9 CYP21A2 POMC PRL
117 estrogen excess 9.8 CYP19A1 PRL SHBG
118 pituitary infarct 9.8 GNRH1 POMC PRL
119 chiasmal syndrome 9.8 GNRH1 POMC PRL
120 hypothalamic disease 9.8 GNRH1 POMC PRL
121 empty sella syndrome 9.8 GNRH1 POMC PRL
122 tsh producing pituitary tumor 9.8 GNRH1 POMC PRL
123 craniopharyngioma 9.8 GNRH1 INS PRL
124 diabetes insipidus, neurohypophyseal 9.8 GNRH1 POMC PRL
125 mccune-albright syndrome 9.8 AMH CYP19A1 PRL
126 acquired metabolic disease 9.8 INS POMC PRL SHBG
127 mycetoma 9.8 CYP17A1 CYP19A1
128 alopecia, androgenetic, 1 9.8 AR CYP19A1 CYP21A2 SHBG SRD5A2
129 mammographic density 9.8 CYP17A1 CYP19A1 PRL
130 body mass index quantitative trait locus 11 9.7 CYP21A2 INS POMC SHBG
131 varicocele 9.7 AMH GNRH1 PRL SHBG
132 achondroplasia 9.7
133 anal canal carcinoma 9.7
134 cleft palate, isolated 9.7
135 diaphragmatic hernia, congenital 9.7
136 neural tube defects 9.7
137 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.7
138 ovarian dysgenesis 1 9.7
139 methemoglobinemia and ambiguous genitalia 9.7
140 smith-lemli-opitz syndrome 9.7
141 opitz gbbb syndrome, type i 9.7
142 wilms tumor 5 9.7
143 premature ovarian failure 7 9.7
144 disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency 9.7
145 wilms tumor 6 9.7
146 diabetes mellitus 9.7
147 diamond-blackfan anemia 9.7
148 male infertility 9.7
149 persistent mullerian duct syndrome 9.7
150 leukodystrophy 9.7
151 hypoparathyroidism 9.7
152 heart disease 9.7
153 patau syndrome 9.7
154 46 xy gonadal dysgenesis 9.7
155 46 xx gonadal dysgenesis 9.7
156 hypogonadism 9.7
157 germ cell cancer 9.7
158 palmoplantar keratosis 9.7
159 lupus erythematosus 9.7
160 5-alpha reductase deficiency 9.7
161 chromosome 7q duplication 9.7
162 germ cells tumors 9.7
163 depression 9.7
164 androgenic alopecia 9.7 AR CYP19A1 PRL SHBG
165 endometrial cancer 9.7 AR CYP19A1 GNRH1 INS SHBG
166 premenstrual tension 9.7 GNRH1 POMC PRL SHBG
167 ectodermal dysplasia 9.7
168 hyperprolactinemia 9.7 GNRH1 POMC PRL SHBG
169 adenomyosis 9.7 CYP19A1 GNRH1 PRL
170 adrenocortical carcinoma, hereditary 9.7 CYP17A1 CYP19A1 CYP21A2 POMC SULT2A1
171 pituitary apoplexy 9.7 GNRH1 INS POMC PRL
172 chromophobe adenoma 9.7 GNRH1 INS POMC PRL
173 pituitary gland disease 9.7 GNRH1 INS POMC PRL
174 hypopituitarism 9.7 GNRH1 INS POMC PRL
175 conn's syndrome 9.6 CYP17A1 CYP21A2 POMC PRL
176 breast disease 9.6 CYP19A1 POMC PRL SHBG
177 adrenal rest tumor 9.6 CYP21A2 GNRH1 POMC PRL
178 female reproductive system disease 9.4 AMH CYP19A1 GNRH1 PRL SHBG
179 pituitary-dependent cushing's disease 9.4 CYP21A2 GNRH1 INS POMC PRL
180 prostate cancer 9.4 AR CYP17A1 CYP19A1 GNRH1 SHBG SRD5A2
181 pseudohermaphroditism 9.2 AMH AMHR2 AR CYP17A1 CYP19A1 HSD17B3
182 anovulation 9.2 AMHR2 CYP19A1 GNRH1 INS PRL SHBG
183 ovarian disease 9.1 AMH CYP19A1 GNRH1 INS PRL SHBG
184 reproductive system disease 9.1 AMH AR CYP17A1 CYP19A1 GNRH1 PRL
185 polycystic ovary syndrome 9.0 CYP17A1 CYP19A1 CYP21A2 GNRH1 INS PRL
186 hyperandrogenism 8.8 CYP17A1 CYP19A1 CYP21A2 GNRH1 INS POMC

Graphical network of the top 20 diseases related to Sex Development Disorder:



Diseases related to Sex Development Disorder

Symptoms & Phenotypes for Sex Development Disorder

MGI Mouse Phenotypes related to Sex Development Disorder:

47 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 AMH AMHR2 AR CYP19A1 GNRH1 INS
2 integument MP:0010771 9.87 AMHR2 AR CYP19A1 GNRH1 INS POMC
3 liver/biliary system MP:0005370 9.73 AR CYP19A1 GNRH1 INS POMC PRL
4 neoplasm MP:0002006 9.63 AMH AMHR2 AR GNRH1 POMC PRL
5 renal/urinary system MP:0005367 9.43 AMHR2 AR CYP19A1 GNRH1 INS POMC
6 reproductive system MP:0005389 9.28 AMH AMHR2 AR CYP17A1 CYP19A1 GNRH1

Drugs & Therapeutics for Sex Development Disorder

Drugs for Sex Development Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 231, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menotropins Approved Phase 4 9002-68-0, 61489-71-2 5360545
2
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
3
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
4
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
5
Drospirenone Approved Phase 4,Not Applicable 67392-87-4 68873
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
7
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-02-2 5743
9
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
11
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
12
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
13
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 1177-87-3
15
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
16
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
17
Metformin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 657-24-9 14219 4091
18
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
19
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
20
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
21
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-22-0, 481-30-1 10204 6013
22
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
26
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-30-3 6037
28
Cortisone Experimental Phase 4,Phase 2 53-06-5 222786
29
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
30 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Chorionic Gonadotropin Phase 4,Not Applicable,Early Phase 1
33 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Follicle Stimulating Hormone Phase 4,Phase 2,Not Applicable
35 Fertility Agents Phase 4,Phase 3,Phase 2,Early Phase 1
36 Drospirenone and ethinyl estradiol combination Phase 4,Not Applicable
37 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
38 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Contraceptive Agents, Male Phase 4,Phase 3,Not Applicable
40 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Not Applicable
41
Cyproterone Phase 4,Not Applicable 2098-66-0 5284537
42 Diuretics, Potassium Sparing Phase 4,Early Phase 1,Not Applicable
43 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Natriuretic Agents Phase 4,Early Phase 1,Not Applicable
45 Hemostatics Phase 4,Not Applicable
46 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 diuretics Phase 4,Early Phase 1,Not Applicable
49 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Not Applicable
50 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
51 Mineralocorticoids Phase 4,Phase 2,Early Phase 1,Not Applicable
52 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
53 Androgen Antagonists Phase 4,Phase 2,Not Applicable
54 Antioxidants Phase 4,Phase 3,Phase 2,Not Applicable
55 Mineralocorticoid Receptor Antagonists Phase 4,Early Phase 1,Not Applicable
56 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
57 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
58 Adrenergic alpha-Agonists Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
59 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
60 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
61 Bronchodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
62 Adrenergic Agonists Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
63 Vasoconstrictor Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
64 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
65 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
66 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
67 Respiratory System Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
68 Hydrocortisone-17-butyrate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
69 Anti-Asthmatic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
70 BB 1101 Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
71 Hydrocortisone hemisuccinate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
72 Mydriatics Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
73 Sympathomimetics Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
74 Adrenergic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
75 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
76 Neurotransmitter Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
77 Adrenergic beta-Agonists Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
78 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
79 Vitamin B Complex Phase 4,Phase 2,Not Applicable
80 Nutrients Phase 4,Phase 3,Phase 2,Not Applicable
81 Vitamin B9 Phase 4,Phase 2,Not Applicable
82 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
83 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
84 Hematinics Phase 4,Not Applicable
85 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
86 Folate Phase 4,Phase 2,Not Applicable
87 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
88 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
89 Anabolic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
90 Testosterone 17 beta-cypionate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
91 Pharmaceutical Solutions Phase 4,Phase 2
92 Methylprednisolone Acetate Phase 4,Phase 3
93 Prednisolone acetate Phase 4,Phase 3
94
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
95
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
96
Oxandrolone Approved, Investigational Phase 3,Phase 2 53-39-4 5878
97
Sodium Citrate Approved, Investigational Phase 3,Phase 2 68-04-2
98
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
99
Metronidazole Approved Phase 3 443-48-1 4173
100
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
101
Vitamin C Approved, Nutraceutical Phase 3,Phase 2 50-81-7 54670067 5785
102
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
103
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 1,Not Applicable 53-43-0 9860744
104
Enclomiphene Investigational Phase 3,Phase 2 15690-57-0
105 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
106 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
107
protease inhibitors Phase 3,Phase 2,Not Applicable
108 HIV Protease Inhibitors Phase 3,Phase 2,Not Applicable
109
Medroxyprogesterone Phase 3 520-85-4 10631
110 Anti-Bacterial Agents Phase 3
111 Anti-Infective Agents Phase 3,Not Applicable
112 Antibiotics, Antitubercular Phase 3
113 Matrix Metalloproteinase Inhibitors Phase 3
114 Antimalarials Phase 3
115 Antiparasitic Agents Phase 3
116 Antiprotozoal Agents Phase 3
117 Laxatives Phase 2, Phase 3
118 Castor Phase 2, Phase 3
119 Cathartics Phase 2, Phase 3
120 Estrogens, Conjugated (USP) Phase 3,Phase 2,Phase 1
121 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
122 Zuclomiphene Phase 3,Phase 2
123 Selective Estrogen Receptor Modulators Phase 3,Phase 2
124 Estrogen Antagonists Phase 3,Phase 2,Phase 1
125 Anticoagulants Phase 3,Phase 2,Not Applicable
126 Citrate Phase 3,Phase 2
127 Clomiphene Phase 3,Phase 2
128 Chelating Agents Phase 3,Phase 2
129 Estrogen Receptor Modulators Phase 3,Phase 2
130 DHEA (Dehydroepiandrosterone) Phase 2, Phase 3,Phase 1,Not Applicable
131 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1,Not Applicable
132 Progestins Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
133 Calcineurin Inhibitors Phase 3
134 Neuroprotective Agents Phase 3
135
Ferrous fumarate Approved Phase 2 141-01-5
136
Leuprolide Approved, Investigational Phase 2,Early Phase 1 53714-56-0 657181 3911
137
Mestranol Approved Phase 2 72-33-3 6291
138
Norethindrone Approved Phase 2,Not Applicable 68-22-4 6230
139
Orlistat Approved, Investigational Phase 2 96829-58-2 3034010
140
Nifedipine Approved Phase 1, Phase 2 21829-25-4 4485
141
Pioglitazone Approved, Investigational Phase 1, Phase 2,Not Applicable 111025-46-8 4829
142
Pancrelipase Approved, Investigational Phase 2 53608-75-6
143
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
144
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
145
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
146
alemtuzumab Approved, Investigational Phase 2 216503-57-0
147
rituximab Approved Phase 2 174722-31-7 10201696
148
Busulfan Approved, Investigational Phase 2 55-98-1 2478
149
Tocopherol Approved, Investigational Phase 2 1406-66-2 14986
150
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
151
Flutamide Approved, Investigational Phase 2,Not Applicable 13311-84-7 3397
152
Fludrocortisone Approved, Investigational Phase 2,Phase 1 127-31-1 31378
153
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
154
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
155
Testolactone Approved, Investigational Phase 2 968-93-4 13769